Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer

Jiang, Yiming; Yu, Danlu; Hou, Guoxin; Jiang, Jialu; Zhou, Qiang; Xu, Xiaofang

doi:10.1042/bsr20190476

Cited by 24 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TSP2 was proposed as prognosis marker in liver fibrosis, 47,48 non-alcoholic fatty liver disease, 49 and different cancers. [50][51][52][53] This study demonstrates that TSP2 is an important player in OA pathogenesis, with a positive correlation observed between TSP2 expression and synovial tissue inflammation, suggesting TSP2 could been developed as novel osteoarthritis marker. The pre-clinical experiments, which utilized TSP2 neutralizing antibody to ameliorate cartilage destruction in OA animal model, also showed the promising response.…”

Section: Discussionmentioning

confidence: 60%

Thrombospondin 2 Promotes IL-6 Production in Osteoarthritis Synovial Fibroblasts via the PI3K/AKT/NF-κB Pathway

Hou¹,

Tang²,

Chen³

et al. 2021

JIR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 60%

Thrombospondin 2 Promotes IL-6 Production in Osteoarthritis Synovial Fibroblasts via the PI3K/AKT/NF-κB Pathway

Hou¹,

Tang²,

Chen³

et al. 2021

JIR

View full text Add to dashboard Cite

“…A clinical study of patients with cancer in China has found signi cant heterogeneity in the distribution of serum THBS2 in various types of cancer compared with healthy control individuals [18]. Thrombospondin-2 might be a diagnostic marker of pancreatic, gastric, non-small-cell lung, and colorectal cancers [2,3,[19][20][21].…”

Section: Discussionmentioning

confidence: 99%

Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic adenocarcinoma and stomach adenocarcinoma: An integrative pan-cancer analysis

Sheng

Liao

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

BackgroundThrombospondin-2 (THBS2) is a versatile glycoprotein that regulates numerous biological functions, including the apoptosis-proliferation balance in endothelial cells, and it has been linked to tumor angiogenesis. However, the role of THBS2 in human cancer remains unknown. This study aimed to determine THBS2 expression in pan-cancer, understand whether THBS2 is associated with its prognosis, and to identify possible roles of THBS2 in tumor immunity and the extracellular matrix (ECM).MethodsData about THBS2 expression in cancers and normal tissues were downloaded from the Genotype-Tissue Expression (GTEx) and UCSC Xena and analyzed using the ONCOMINE database, Perl programming language, and the Gene Expression Profiling and Interactive Analyses vision 2 (GEPIA2) web server. Survival prognosis was analyzed using the survival, survminer, and forestplot packages in R v. 4.0.3 and the limma package in R . Immune and matrix components were also analyzed using R v. 4.0.3. Most importantly, we partially validated the role and mechanism of THBS2 in pancreatic and gastric cancers in vitro using PANC1 and BGC-823 cell lines.ResultsThrombospondin-2 was significantly overexpressed in 17 of the 33 investigated cancers, and linked to a poor prognosis in pan-cancer survival analysis, especially in adrenocortical (ACC), kidney renal papillary cell (KIRP), and stomach (STAD) carcinomas, kidney chromophobe (KICH), and pancreatic adenocarcinoma (PAAD). Immune infiltration and THBS2 expression were also related. The expression of THBS2 has been linked to immune scores, stromal scores, and immune checkpoint markers in various cancers. The PPI network revealed that THBS2 is associated with multiple extracellular matrix proteins and immune proteins. Knockdown of THBS2 decreased the expression of CD47 and MMP-2 as well as the proliferation, migration, and invasion of PANC1 and BGC-823 cells in vitro. ConclusionsOur findings suggested that THBS2 could be a prognostic biomarker that acts as a bridge between the ECM and immune infiltration in various types of cancers, and that it promoted the progression of numerous types of cancers, especially PAAD and STAD.

show abstract

“…Seeking effective biomarker is important to reduce incidence rate of NSCLC. Several genes including bromodomain PHD nger transcription factor (BPTF) [18], Serum thrombospondin-2 [19], CTAPIII/CXCL7 [20], c-MET [21], and so on. Accumulating evidence indicates that miRNAs can be biomarker of NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of microRNA-126 Suppresses Non-Small-Cell Lung Cancer via Inhibiting PI3K-AKT-mTOR Pathway

Chen

Ping

et al. 2021

Preprint

View full text Add to dashboard Cite

Background As one of the most common cause of cancer death in the world, lung cancer causes approximate 1.6 million deaths annually. Among, NSCLC accounts approximately 85% of patients in whole lung cancer patients. As one of miRNAs, miR-126 closely involves in pathogenesis of several types of cancers including colorectal, prostate, bladder and gastric cancer, and so on. Thus, the present study aims to investigate effects of miR126 on pathogenesis of NSCLC. In the study, two lung cancer cell lines including A549 and H1650 were used. Results It was found that expression of miR126 was decreased in PBMC of NSCLC patients compared to healthy control. Expression of miR126 was decreased in cancer tissue compared to paracancerous tissues in NSCLC patients. MiR-126 KD remarkably increased expression of apoptosis genes including caspase3 and capsae9, and decreased cell viability in lung cancer cells including A549 and H1650 cells. Interesting, In Silico analysis indicated that miR-126 could target PI3K signaling pathway, which was confirmed by WB assay. KD of PI3KR2 compromised promotion of miR-126 on cell apoptosis. Similarly, it was found that KD of mTOR compromised promotion of miR-126 on cell apoptosis. Conclusions Thus, the present study confirmed that miR-126 plays an important role in apoptosis of lung cells via mTOR signaling pathway. miR-126 might be a potential therapeutic target for developing novel drugs against NSCLC.

show abstract

Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer

Cited by 24 publications

References 31 publications

Thrombospondin 2 Promotes IL-6 Production in Osteoarthritis Synovial Fibroblasts via the PI3K/AKT/NF-κB Pathway

Thrombospondin 2 Promotes IL-6 Production in Osteoarthritis Synovial Fibroblasts via the PI3K/AKT/NF-κB Pathway

Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic adenocarcinoma and stomach adenocarcinoma: An integrative pan-cancer analysis

Knockdown of microRNA-126 Suppresses Non-Small-Cell Lung Cancer via Inhibiting PI3K-AKT-mTOR Pathway

Contact Info

Product

Resources

About